SCHEMBL15915437

SCHEMBL15915437

CCOC(CCCC(N)=O)OCC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.36
KMT2A Q03164 3/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
EPHX1 P07099 1/20 0.35
CYP1A2 P05177 3/20 0.35
MEN1 O00255 2/20 0.35
SOAT1 P35610 2/20 0.35
FAAH O00519 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 1/20 0.35
FOLH1 Q04609 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CNR1 P21554 1/20 0.33
DDAH1 O94760 2/20 0.33
NOS1 P29475 1/20 0.33
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5611920 0.92 KMT2A (0.41) ALOX15KMT2ABLMPMP22EPHX1
SCHEMBL2844179 0.89 KMT2A (0.41) ALOX15KMT2ABLMPMP22EPHX1
SCHEMBL9517412 0.83 AKR1B1 (0.44) ALOX15KMT2AMEN1LMNAGABRP
SCHEMBL30104283 0.82 FAAH (0.59) ALOX15KMT2ABLMCYP1A2MEN1
SCHEMBL7026501 0.82 NOS1 (0.39) ALOX15KMT2ABLMEPHX1CYP1A2
SCHEMBL8430447 0.79 CYP1A2 (0.53) ALOX15KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL27563607 0.79 CA1 (0.35) ALOX15KMT2ABLMPMP22CYP1A2
SCHEMBL8434211 0.79 TSHR (0.54) KMT2AEPHX1CYP1A2MEN1LMNA
SCHEMBL28741965 0.79 CA1 (0.35) ALOX15KMT2AEPHX1CYP1A2MEN1
SCHEMBL26133367 0.79 CA1 (0.35) ALOX15KMT2ABLMPMP22CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682996-B2 Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Prism BioLab Co., Ltd. (JP) 2017-06-20 US disclosed
US-20150376204-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS Prism BioLab Co., Ltd. (JP) 2015-12-31 US disclosed
US-9126981-B2 Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions Prism BioLab Co., Ltd. (JP) 2015-09-08 US disclosed
US-20140221657-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS PRISM BIOLAB CORPORATION (JP) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376204-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS CREBBP, CTNNB1, CTNNA1 ALOX15 2829/4885KMT2A 1322/4885BLM 455/4885
US-20140221657-A1 ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS CREBBP, CTNNB1, CTNNA1 ALOX15 2829/4885KMT2A 1322/4885BLM 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.